Heart Failure and Chronic Kidney Disease in Type 2 Diabetes

1. Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455-469.10.1093/eurheartj/eht386Search in Google Scholar

2. Löfman I, Szummer K, Hagerman I, et al. Prevalence and prognostic impact of kidney disease on heart failure patients. Open Heart. 2016;3:e000324.10.1136/openhrt-2015-000324Search in Google Scholar

3. Shiba N, Shimokawa H. Chronic kidney disease and heart failure — Bidirectional close link and common therapeutic goal. J Cardiol. 2011;57:8-17.10.1016/j.jjcc.2010.09.004Search in Google Scholar

4. International Diabetes Federation. IDF Diabetes Atlas, 2015. Available at: http://www.diabetesatlas.orgSearch in Google Scholar

5. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12:73-81.10.1038/nrneph.2015.173Search in Google Scholar

6. Roberts AW, Clark AL, Witte KK. Review article: Left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease — do we need to screen our patients? Diab Vasc Dis Res. 2009;6:153-163.Search in Google Scholar

7. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55:2154-2162.10.1007/s00125-012-2579-0Search in Google Scholar

8. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29-34.10.1016/0002-9149(74)90089-7Search in Google Scholar

9. American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care. 2017;40(Suppl1):S1-S135.10.2337/dci17-000728637893Search in Google Scholar

10. Re RN. A Reassessment of the Pathophysiology of Progressive Cardiorenal Disorders. Med Clin North Am. 2017;101:103-115.10.1016/j.mcna.2016.08.00727884222Search in Google Scholar

11. Schefold JC, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12:610-623.10.1038/nrneph.2016.11327573728Search in Google Scholar

12. Karnib HH, Ziyadeh FN. The cardiorenal syndrome in diabetes mellitus. Diabetes Res Clin Pract. 2010;89:201-208.10.1016/j.diabres.2010.05.02220599286Search in Google Scholar

13. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2:843-851.10.1016/S2213-8587(14)70031-2Search in Google Scholar

14. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-596.10.1016/j.jacc.2008.05.068285696019215833Search in Google Scholar

15. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582-588.10.1016/j.jacc.2008.08.08019215832Search in Google Scholar

16. Ramos HR, Birkenfeld AL, de Bold AJ. INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. Endocr Connect. 2015;4:R25-R36.10.1530/EC-15-0018448517726115665Search in Google Scholar

17. Farmakis D, Filippatos G, Kremastinos DT, Gheorghiade M. Vasopressin and vasopressin antagonists in heart failure and hyponatremia. Curr Heart Fail Rep. 2008;5:91-96.10.1007/s11897-008-0015-z18765079Search in Google Scholar

18. Lekawanvijit S, Krum H. Cardiorenal syndrome: acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins. J Physiol. 2014;592:3969-3983.10.1113/jphysiol.2014.273078419800824907309Search in Google Scholar

19. Rubattu S, Mennuni S, Testa M, et al. Pathogenesis of chronic cardiorenal syndrome: is there a role for oxidative stress? Int J Mol Sci. 2013;14:23011-23032.Search in Google Scholar

20. Ma RC. Genetics of cardiovascular and renal complications in diabetes. J Diabetes Investig. 2016;7:139-154.10.1111/jdi.12391477366127042264Search in Google Scholar

21. Hundae A, McCullough PA. Cardiac and renal fibrosis in chronic cardiorenal syndromes. Nephron Clin Pract. 2014;127:106-112.10.1159/00036370525343831Search in Google Scholar

22. Charytan DM, Fishbane S, Malyszko J, McCullough PA, Goldsmith D. Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. Am J Kidney Dis. 2015;66:196-120.10.1053/j.ajkd.2014.12.016451668325727384Search in Google Scholar

23. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818-827.10.1016/j.jacc.2008.04.06118755344Search in Google Scholar

24. Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol. 2008;101:223-230.10.1016/j.amjcard.2007.07.06718178411Search in Google Scholar

25. Battiprolu PK, Gillette TG, Wang ZV, Lavandero S, Hill JA. Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets. Drug Discov Today Dis Mech. 2010;7:e135-e143.10.1016/j.ddmec.2010.08.001302647321274425Search in Google Scholar

26. Garud MS, Kulkarni YA. Hyperglycemia to nephropathy via transforming growth factor beta. Curr Diabetes Rev. 2014;10:182-189.10.2174/157339981066614060610364524919657Search in Google Scholar

27. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia. 2008;51:714-725.Search in Google Scholar

28. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16:120-126.10.1016/j.tem.2005.02.00315808810Search in Google Scholar

29. Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2016;90:84-93.10.1016/j.yjmcc.2015.12.011471874026705059Search in Google Scholar

30. Yilmaz S, Canpolat U, Aydogdu S, Abboud HE. Diabetic Cardiomyopathy; Summary of 41 Years. Korean Circ J. 2015;45:266-272.10.4070/kcj.2015.45.4.266452110326240579Search in Google Scholar

31. Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin. 2012;8:609-617.10.1016/j.hfc.2012.06.005345706522999243Search in Google Scholar

32. Sweiss N, Sharma K. Adiponectin effects on the kidney. Best Pract Res Clin Endocrinol Metab. 2014;28:71-79.10.1016/j.beem.2013.08.002425256724417947Search in Google Scholar

33. Nasrallah MP, Ziyadeh FN. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol. 2013;33:54-65.10.1016/j.semnephrol.2012.12.00523374894Search in Google Scholar

34. Rüster C1, Wolf G. Adipokines promote chronic kidney disease. Nephrol Dial Transplant. 2013;28(Suppl4):iv8-iv14.10.1093/ndt/gft19124179016Search in Google Scholar

35. Ybarra J, Sánchez-Hernández J, Vilallonga R, Romeo JH. Differential associations between glomerular filtration rate and duration of obesity depending on the presence or absence of left ventricular diastolic dysfunction. Eur J Intern Med. 2016;32:47-52.10.1016/j.ejim.2016.02.01626935097Search in Google Scholar

36. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891-975.10.1002/ejhf.59227207191Search in Google Scholar

37. Fenske W, Athanasiou T, Harling L, Drechsler C, Darzi A, Ashrafian H. Obesity-related cardiorenal disease: the benefits of bariatric surgery. Nat Rev Nephrol. 2013;9:539-551.10.1038/nrneph.2013.14523917797Search in Google Scholar

38. Cahn A, Cernea S, Raz I. Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. Rev Endocr Metab Disord. 2016;17:117-127.10.1007/s11154-016-9351-627106831Search in Google Scholar

39. Mummidi S, Das NA, Carpenter AJ, et al. Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo. J Mol Cell Cardiol. 2016;98:95-102.10.1016/j.yjmcc.2016.07.00627423273Search in Google Scholar

40. Soraya H, Clanachan AS, Rameshrad M, Maleki-Dizaji N, Ghazi-Khansari M, Garjani A. Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction. Eur J Pharmacol. 2014;737:77-84.10.1016/j.ejphar.2014.05.00324842192Search in Google Scholar

41. El Messaoudi S, Rongen GA, Riksen NP. Metformin therapy in diabetes: the role of cardioprotection. Curr Atheroscler Rep. 2013;15:314.10.1007/s11883-013-0314-z23423523Search in Google Scholar

42. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007;30:2148-2153.10.2337/dc07-014117536074Search in Google Scholar

43. Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol. 2016;8:61-81.10.2147/CPAA.S82008492277527382338Search in Google Scholar

44. Aguilar D. Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease: A Clinical Conundrum. Circ Heart Fail. 2016;97pii:e003316.10.1161/CIRCHEARTFAILURE.116.00331627413031Search in Google Scholar

45. Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373:2247-2257.10.1056/NEJMoa1509225Search in Google Scholar

46. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311-322.10.1056/NEJMoa1603827Search in Google Scholar

47. von Scholten BJ, Hansen TW, Goetze JP, Persson F, Rossing P. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complications. 2015;29:670-674.10.1016/j.jdiacomp.2015.04.004Search in Google Scholar

48. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.10.1056/NEJMoa1307684Search in Google Scholar

49. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067-2076.10.1016/S0140-6736(14)62225-XSearch in Google Scholar

50. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373:232-242.10.1056/NEJMoa150135226052984Search in Google Scholar

51. Cernea S, Cahn A, Raz I. Saxagliptin for the treatment of diabetes — a focus on safety. Expert Opin Drug Saf. 2016;15:697-707.10.1517/14740338.2016.115967526923222Search in Google Scholar

52. Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015;38:696-705.10.2337/dc14-185025552421Search in Google Scholar

53. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117-2128.10.1056/NEJMoa150472026378978Search in Google Scholar

54. Rajasekeran H, Lytvyn Y, Cherney DZ. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int. 2016;89:524-526.10.1016/j.kint.2015.12.03826880444Search in Google Scholar

55. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care. 2016;39:1108-1114.10.2337/dc16-033027289126Search in Google Scholar

56. Carubelli V, Lombardi C, Gorga E, Ravera A, Metra M, Mentz RJ. Cardiorenal Interactions. Heart Fail Clin. 2016;12:335-347.10.1016/j.hfc.2016.03.00227371511Search in Google Scholar